Thousand Oaks News
-
Amgen Inc.’s Neulasta and Neupogen and a similar blood-boosting drug from Teva Pharmaceutical Industries Ltd. may help people survive after a nuclear attack, U.S. regulators said.
-
Amgen Inc., the world’s largest biotechnology company, declined the most in four years after reporting sales growth that missed analysts’ estimates.
-
Chili peppers and migraines have traits in common, a fact scientists are exploiting to develop drugs capable of preventing the debilitating headache’s painful symptoms before they attack.
-
Biotechnology companies worldwide boosted profit by 37 percent to a record $5.2 billion in 2012, partly by tempering growth in research-and-development spending, according to Ernst & Young.
-
Pfizer Inc., the world’s biggest drugmaker, will pay closely held Bind Therapeutics Inc. as much as $200 million per potential drug to develop medicines using its nanotechnology platform.
-
Health-care stocks are leading gains in U.S. equities this year for the first time since 1998 as companies cut costs and investors speculate an expansion of insurance programs will benefit hospitals and insurers.
-
The Charity Angels wear pink polo shirts and white skirts when they patrol the greens and fairways of Sherwood Country Club in Thousand Oaks, California.
-
Hedge-fund manager Philip Falcone, beset by declining assets, federal securities regulators and the bankruptcy of his largest investment, is borrowing money against personal real estate he bought during better days.
-
Amgen Inc., the world’s largest biotechnology company, raised its full-year profit forecast after federal tax settlements to an adjustment in charges for this quarter.
-
The U.S. Supreme Court made it easier for shareholders to press class action securities-fraud suits, ruling that Amgen Inc. must defend against claims that it misled investors about the safety of two drugs for anemia.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page